Pharmacodynamic and pharmacokinetic interactions of selective serotonin re-uptake inhibiting antidepressants (SSRIs) with other psychotropic drugs

References

• Feighner J P., Boyer W F. Selective serotonin re-uptake inhibitors. J Wiley & Sons, Chichester 1991; 168pp
   Google Scholar
• Nelson J C., Mazure C M., Bowers MB, Jr, Jatlow P I. A preliminary open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch Gen Psychiatry 1991; 48: 303–7
   PubMed Web of Science ®Google Scholar
• Seth R, Jennings A L., Bindman J, Phillips J, Bergmann K. Combination treatment with noradrenalin and serotonin re-uptake inhibitors in resistant depression. Br J Psychiatry 1992; 161: 562–5
   Google Scholar
• Fava M, Rosenbaum J F., Cohen L, Reiter S, McCarthy M, Steingard R, Clancy K. High-dose fluoxetine in the treatment of depressed patients not responsive to a standard dose of fluoxetine. J Affective Disord 1992; 25: 229–34
   PubMed Web of Science ®Google Scholar
• Bell I R., Cole J O. Fluoxetine induces elevation of desipramine level and exacerbation of geriatric nonpsychotic depression. J Clin Psychopharmacol 1988; 8: 447–8
   PubMed Web of Science ®Google Scholar
• Vaughan D A. Interaction of fluoxetine with tricyclic antidepressants. Am J Psychiatry 1988; 145: 1478
   PubMed Web of Science ®Google Scholar
• Downs J M., Downs A D., Rosenthal T L., Deal N, Akiskal H S. Increased plasma tricyclic antidepressant concentrations in two patients concurrently trea. J Clin Psychiatry 1989; 50: 226–7
   PubMed Web of Science ®Google Scholar
• Aranow R B., Hudson J I., Pope H G., Grady T A., Laage T A., Bell I R., Cole J O. Elevated antidepressant levels after addition of fluoxetine. Am J Psychiatry 1989; 146: 911–3
   PubMed Web of Science ®Google Scholar
• Eisen A. Fluoxetine and desipramine: a strategy for augmenting antidepressant response. Pharmacopsychiat 1992; 1989: 272–3
   Google Scholar
• Schraml F, Benedetti G, Hoyle K, Clayton A. Fluoxetine and nortriptyline combination therapy. Am J Psychiatry 1992; 146: 1636–7
   Google Scholar
• DeMaso D R., Hunter T A. Combining fluoxetine with desipramine. J Am Acad Child Adolesc Psychiatry 1992; 29: 151
   Google Scholar
• Preskorn S H., Beber J H., Faul J C., Hirschfeld R MA. Serious adverse effects of combining fluoxetine and tricyclic antidepressants. Am J Psychiatry 1992; 147: 532
   Google Scholar
• Westermeyer J. Fluoxetine-induced tricyclic toxicity: extent and duration. J Clin Pharmacol 1991; 31: 388–92
   PubMed Web of Science ®Google Scholar
• Kahn D G. Increased plasma nortriptyline concentration in a patient cotreated with fluoxetine. J Clin Psychiatry 1990; 51: 36
   Google Scholar
• Müller N, Brockmöller J, Roots I. Extremely long plasma half-life of amitriptyline in a woman with the cytochrome P450IID6 29/29-kilobase wild-type allele—a slowly reversible interaction with fluoxetine. Ther Drug Monit 1991; 13: 533–6
   PubMed Web of Science ®Google Scholar
• Vandel S, Bertschy G, Bonin B, Nezelof S, François TH, Vandel B, Scchter D, Bizouard P. Tricyclic antidepressant plasma levels after fluoxetine addition. Neuropsychobiology 1992; 25: 202–7
   PubMed Web of Science ®Google Scholar
• Rosenstein D L., Takeshita J, Nelson J C. Fluoxetine-induced elevation and prolongation of tricyclic levels in overdose. Am J Psychiatry 1991; 148: 807
   PubMed Web of Science ®Google Scholar
• Bertschy G, Vandel S, Vandel B, Allers G, Volmat R. Fluvoxamine-tricyclic antidepressant interaction—an accidental finding. Eur J Clin Pharmacol 1991; 40: 119–20
   PubMed Web of Science ®Google Scholar
• Spina E, Campo G M., Avenoso A, Pollicino M A., Caputi A P. Interaction between fluvoxamine and imipramine/desipramine in four patients. Ther Drug Monit 1992; 14: 194–6
   PubMedGoogle Scholar
• Bertschy G, Vandel S, Nezelof S, Bizouard P, Bechtel P. L'interaction fluvoxamine-antidépresseurs tricycliques: quelques précisions. Thérapie 1993; 48: 59–72
   Google Scholar
• Silver H, Nassar A. Fluvoxamine improves negative symptoms in treated chronic schizophrenia: an add-on double-blind placebo-controlled study. Biological Psychiatry 1992; 31: 698–704
   PubMed Web of Science ®Google Scholar
• Baettig D, Bondolfi G, Montaldi S, Amey M, Baumann P. Pharmacokinetic interaction of citalopram and tricyclic antidepressants. Eur J Clin Pharmacol 1993; 44: 403–05
   PubMed Web of Science ®Google Scholar
• Price L H., Charney D S., Delgado P L., Heninger G R. Fenfluramine augmentation in tricyclic-refractory depression. J Clin Psychopharmacol 1990; 10: 312–17
   Google Scholar
• Lock J D., Gwirtsman H E., Targ E F. Possible adverse drug interactions between fluoxetine and other psychotropics. J Clin Psychopharmacol 1990; 10: 383–4
   PubMed Web of Science ®Google Scholar
• Pach Ergebnisse J., Kasuistik. Pharmakotoxische Psychose und extrapyramidalmotorisches Syndrom. Nervenarzt 1992; 63: 575–6
   Google Scholar
• Achamallah N S. Visual hallucinations after combining fluoxetine and dextromethorphan. American Journal of Psychiatry 1992; 149: 1406
   PubMed Web of Science ®Google Scholar
• Grimsley S R., Jann M W., Carter J G., D'Mello A P., D'Souza M J. Increased carbamazepine plasma concentrations after fluoxetine coadministration Clin Pharmacol Ther 1991; 50: 10–15
   Google Scholar
• Lemberger L, Rowe H, Bosomworth J C., Tenbarge J B., Bergström RF. The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam. Clin Pharmacol Ther 1988; 43: 412–19
   PubMed Web of Science ®Google Scholar
• Brøsen K, Gram L F. Clinical significance of the sparteine/debrisoquine oxidation polymorphism. Eur J Clin Pharmacol 1989; 36: 537–47
   PubMed Web of Science ®Google Scholar
• Suckow R F., Roose S P., Cooper T B. Effect of fluoxetine on plasma desipramine and 2-hydroxydesipramine. Biol Psychiatry 1992; 31: 200–4
   Google Scholar
• Bergstrom R F., Peyton A L., Lemberger L. Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction. Clin Pharmacol Ther 1992; 51: 239–48
   PubMed Web of Science ®Google Scholar
• Crewe H K., Lennard M S., Tucker G T., Woods F R., Haddock R E. The effect of selective serotonin reuptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 1992; 34: 262–5
   PubMed Web of Science ®Google Scholar
• Skjelbo E, Brøsen K. Inhibitors of imipramine metabolism by human liver microsomes. Br J Clin Pharmacol 1992; 34: 256–61
   PubMed Web of Science ®Google Scholar
• Hyttel J, Bogeso K P., Perregaard J, Sanchez C. The pharmacological effect of citalopram resides in the (S)-(+)-enantiomer. J Neural Transm 1992; 88: 157–60
   PubMed Web of Science ®Google Scholar
• Wong D T., Fuller R W., Robertson D W. Fluoxetine and its two enantiomers as selective serotonin uptake inhibitors. Acta Pharmaceutica Nordica 1990; 2: 171–9
   PubMedGoogle Scholar
• Fuller R W., Snoddy H D., Krushinski J H., Robertson D W. Comparison of norfluoxetinc enantiomers as serotonin uptake inhibitors in vivo. Neuropharmacology 1992; 31: 997–1000
   PubMed Web of Science ®Google Scholar
• Torok-Both G A., Baker G B., Coutts R T., McKenna K F., Aspeslet U. Simultaneous determination of fluoxetine and norfluoxetine in biological samples by gas chromatography with electron-capture de tection. J Chromatogr Biomed Appl 1992; 579: 99–106
   Google Scholar
• Potts B D., Parli C J. Analysis of the enantiomers of fluoxetine and norfluoxetine in plasma and tissue using chiral derivatization and normal-phase liquid chromatography. J Liq Chromatogr 1992; 15: 665–81
   Web of Science ®Google Scholar
• Grinshpoon A, Berg Y, Mozes T, Mester R, Weizman A. Seizures induced by combined levomepromazine-fluvoxamine treatment. Int Clin Psychopharmacol 1993; 8: 61–2
   Google Scholar
• Bertschy G, Baumann P, Eap C B., Baettig D. Metabolic interaction between methadone and fluvoxamine in addict patients. Ther Drug Monit 1993, (in press).
   Google Scholar
• Seifritz E, Holsboer-Trachsler E, Hemmeter U., Eap C B., Baumann P. Panic attacks and aggravation of depression under citalopram or fluvoxamine-trimipramine comedication. Fluvoxamine induced inhibition of trimipramine metabolism. E Neuropsychopharmacol 1993, (in press).
   Google Scholar
• Brøsen K, Skjelbo E, Rasmussen B B., Poulsen H E., Loft S. Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol 1993; 45: 1211–4
   PubMed Web of Science ®Google Scholar